Russian Extreme Hypertriglyceridemia Registry
ConditionHypertriglyceridemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorRussian Cardiology Research and Production Center
About this trial
The REGGI registry is a prospective, multicenter observational registry in Russia designed to collect data on patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L). The registry aims to describe the clinical, demographic, and molecular-genetic characteristics of patients, as well as current diagnostic approaches and treatment patterns in real-world practice. The collected data may inform future research and support improvements in patient care.
Eligibility criteria
Qualifiers
Patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L), confirmed by at least two independent measurements.
Written informed consent from the patient or legal guardian.
No age restrictions.
Disqualifiers
Patients whose extreme hypertriglyceridemia is caused by alcohol abuse, uncontrolled diabetes, or other medical conditions, unless extreme hypertriglyceridemia is confirmed after controlling the underlying condition.
Lack of informed consent.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 1 trial groupLocations
6Astrakhan State Medical University Astrakhan Russia
Chelyabinsk State Medical Academy Chelyabinsk Russia
Kaluga City Clinical Hospital No. 5 Kaluga Russia
State Medical University Kazan' Russia
Sponsors and collaborators
Russian Cardiology Research and Production Center
Lead sponsor
Research Centre for Medical Genetics, Russian Federation
Collaborator
Source ClinicalTrials.gov